PRRU.F Stock Overview
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Immutep Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.26 |
| 52 Week High | AU$0.31 |
| 52 Week Low | AU$0.14 |
| Beta | 1.83 |
| 1 Month Change | 10.04% |
| 3 Month Change | 14.48% |
| 1 Year Change | 53.92% |
| 3 Year Change | -17.78% |
| 5 Year Change | 2,541.00% |
| Change since IPO | 340.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| PRRU.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.0% | 0.4% | 1.0% |
| 1Y | 53.9% | 0.9% | 21.9% |
Return vs Industry: PRRU.F exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: PRRU.F exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| PRRU.F volatility | |
|---|---|
| PRRU.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRRU.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PRRU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Marc Voigt | www.immutep.com |
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.
Immutep Limited Fundamentals Summary
| PRRU.F fundamental statistics | |
|---|---|
| Market cap | US$348.61m |
| Earnings (TTM) | -US$26.39m |
| Revenue (TTM) | US$2.56m |
136.1x
P/S Ratio-13.2x
P/E RatioIs PRRU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRRU.F income statement (TTM) | |
|---|---|
| Revenue | AU$3.93m |
| Cost of Revenue | AU$37.72m |
| Gross Profit | -AU$33.79m |
| Other Expenses | AU$6.71m |
| Earnings | -AU$40.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | -859.57% |
| Net Profit Margin | -1,030.32% |
| Debt/Equity Ratio | 0.8% |
How did PRRU.F perform over the long term?
See historical performance and comparison